Oxford
BioDynamics
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Issue of shares in lieu of
salary,
Director / PDMR shareholdings
&
Total voting rights
Oxford, UK - 24 December
2024 - Oxford BioDynamics,
Plc (AIM: OBD, the Company), a precision
clinical diagnostics company bringing specific and sensitive tests
to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, announces the issue of
2,742,657 ordinary shares of 1 pence each ("Ordinary Shares") at a
price of 1.1 per share (the "New Ordinary Shares") to its
directors, PDMRs and certain other senior staff members to satisfy
part of their salaries and fees, in line with the Company's ongoing
strategy to preserve its cash resources as announced on 14 October
2024. The issue price is equal to the closing market price of the
Company's Ordinary Shares on 23 December 2024, being the last
practicable date prior to the issue of the New Ordinary
Shares.
The New Ordinary Shares being issued
have been allocated to the following directors and
PDMRs:
|
Director / PDMR
|
Position
|
Number of New Ordinary Shares
issued
|
Resultant shareholding in the
Company
|
% of the issued share capital
of the Company
|
|
Dr Alexandre Akoulitchev
|
Chief Scientific Officer
|
229,584
|
7,562,296
|
2.37%
|
|
Paul Stockdale
|
Chief Financial Officer
|
212,547
|
1,077,919
|
0.34%
|
|
Matthew Wakefield
|
Non-Executive Chairman
|
115,949
|
1,616,614
|
0.51%
|
|
Dr David Holbrook
|
Non-Executive Director
|
58,671
|
159,964
|
0.05%
|
|
Thomas Guiel
|
Chief Operating Officer
|
261,343
|
1,288,146
|
0.40%
|
|
Dr Ewan Hunter
|
Chief Data Officer
|
194,720
|
722,754
|
0.23%
|
Application has been made for the
New Ordinary Shares to be admitted to trading on AIM ("Admission")
and it is expected that Admission will occur at 8.00 a.m. on or
around 31 December 2024. The New Ordinary Shares have been issued
as fully paid and rank pari passu in all respects with the existing
Ordinary Shares.
Following Admission, the Company's
issued share capital will consist of 319,319,226 Ordinary Shares.
There are no shares held in treasury. Therefore, the Company's
total number of Ordinary Shares in issue and voting rights will be
319,319,226 and this figure may be used by Shareholders from
Admission as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Further details of the PDMR dealings
are included below. This information has been provided in
accordance with Article 5(1)(b) of the Market Abuse Regulation (EU)
No 596/2014 which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018.
-Ends-
For
more information:
|
Oxford BioDynamics
Plc
Matthew Wakefield, Non-Executive
Chairman
Paul Stockdale, CFO
|
+44
(0)1865 518910
|
|
Shore Capital
(Nominated Adviser and Broker to OBD)
Stephane Auton
Lucy Bowden
|
+44 (0)20
7408 4090
|
|
WG Partners
(Joint Broker to
OBD)
David Wilson / Claes Spång /
Satheesh Nadarajah / Erland Sternby
|
+44
(0)20 3705 9330
|
|
Oak Securities
(Joint Broker to OBD)
Jerry
Keen / Henry Clarke
|
+44
(0)20 3973 3678
|
|
Vigo
Consulting
(Media / Analyst enquiries
for OBD)
Rozi Morris
|
+44 (0)20
7390 0230
obd@vigoconsulting.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
an international biotechnology company, advancing personalized
healthcare by developing and commercializing precision clinical
diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products:
the EpiSwitch® PSE
(EpiSwitch Prostate Screening test)
and EpiSwitch® CiRT
(Checkpoint Inhibitor Response Test) blood tests.
PSE boosts the predictive accuracy of a PSA test from 55% to 94%
when testing the presence or absence of prostate cancer.
CiRT is a highly accurate (85%) predictive
response test to immuno-oncology checkpoint inhibitor
treatments.
The tests are based on OBD's
proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring
of biomarkers to diagnose patients or determine how individuals
might respond to a disease or treatment.
OBD's clinical smart tests have the
potential to be used across a broader range of indications, and new
tests are being developed in the areas of oncology, neurology,
inflammation, hepatology and animal health.
The Group's headquarters and UK
laboratories are in Oxford, UK. Its US operations and clinical
laboratory are in Maryland, USA, along with a reference laboratory
in Penang, Malaysia.
OBD is listed on the London Stock
Exchange's AIM (LSE: OBD). For more information, please visit the
Company's website, www.oxfordbiodynamics.com,
X (@OxBioDynamics) or LinkedIn.
The notifications below, made in
accordance with the requirements of the UK Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1) Dr Alexandre
Akoulitchev
2) Paul
Stockdale
3) Matthew
Wakefield
4) Dr David
Holbrook
5) Thomas
Guiel
6) Dr Ewan
Hunter
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
1) Chief Scientific
Officer, Director
2) Chief Financial
Officer, Director
3) Non-Executive
Director
4) Non-Executive
Director
5) Chief Operating
Officer, PDMR
6) Chief Data Officer, PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford Biodynamics plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Issue of New Ordinary Shares in lieu
of salary
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1)
|
1.1p
|
229,584
|
|
2)
|
1.1p
|
212,547
|
|
3)
|
1.1p
|
115,949
|
|
4)
|
1.1p
|
58,671
|
|
5)
|
1.1p
|
261,343
|
|
6)
|
1.1p
|
194,720
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A - single transactions
|
|
e)
|
Date of the transaction
|
23 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|